Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Net Margin (2017 - 2026)

Organogenesis Holdings has reported Net Margin over the past 9 years, most recently at 15.57% for Q4 2025.

  • For Q4 2025, Net Margin rose 1093.0% year-over-year to 15.57%; the TTM value through Dec 2025 reached 2.81%, up 300.0%, while the annual FY2025 figure was 3.55%, 374.0% up from the prior year.
  • Net Margin for Q4 2025 was 15.57% at Organogenesis Holdings, up from 9.63% in the prior quarter.
  • Over five years, Net Margin peaked at 39.88% in Q4 2021 and troughed at 24.91% in Q1 2025.
  • A 5-year average of 4.24% and a median of 4.58% in 2024 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: skyrocketed 3612bps in 2021 and later tumbled -3169bps in 2022.
  • Year by year, Net Margin stood at 39.88% in 2021, then crashed by -79bps to 8.19% in 2022, then plummeted by -107bps to 0.57% in 2023, then surged by 914bps to 4.64% in 2024, then skyrocketed by 236bps to 15.57% in 2025.
  • Business Quant data shows Net Margin for ORGO at 15.57% in Q4 2025, 9.63% in Q3 2025, and 12.08% in Q2 2025.